| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.26 | 4e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.26 | 1e-12 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.23 | 1e-06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.22 | 4e-05 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.22 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.21 | 5e-05 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.2 | 5e-05 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-08 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.2 | 3e-07 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.2 | 6e-08 |